Ipatasertib (GDC-0068) 化学構造
分子量: 458



Quality Control & MSDS


  • Compare Akt Inhibitors
  • 研究分野
  • Combination Therapy



製品説明 Ipatasertib (GDC-0068)は、5nM、18nMと8nMのIC50でAkt1、Akt2とAkt3を目標としている非常に選択的な汎Akt阻害剤です。
ターゲット Akt1 Akt2 Akt3
IC50 5 nM 18 nM 8 nM [1]
In vitro試験 Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69 nM, and 860 nM, respectively). GDC-0068 displays >100-fold selectivity for Akt over PKA with IC50 of 3.1 μM. In LNCaP, PC3 and BT474M1 cells, GDC-0068 treatment inhibits the phosphorylation of the Akt substrate, PRAS40 with IC50 of 157 nM, 197 nM, and 208 nM, respectively. Furthermore, GDC-0068 selectively inhibits cell cycle progression and viability of cancer cell lines driven by Akt signaling, including those with defects in the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2, with strongest effects in HER2+ and Luminal subtypes. [1-4]
In vivo試験 Oral administration of GDC-0068 in PC3 prostate tumor xenografts model induces down-regulation of p-PRAS40. In BT474-Tr xenografts, GDC-0068 treatment reduces pS6 and peIF4G levels, re-localizes FOXO3a to nucleus, and induces feedback upregulation of HER3 and pERK. Administration of GDC-0068 exhibits potent antitumor efficacy in multiple xenograft tumor models, including the PTEN-deficient prostate cancer models LNCaP and PC3, the PIK3CA H1047R mutant breast cancer model KPL-4, and MCF7-neo/HER2 tumor model. [1-4]
臨床試験 A Phase I study of GDC-0068 in patients with refractory solid tumors is ongoing.

プロトコル (参考用のみ)

動物実験: [1]

動物モデル Female nude mice bearing LNCaP, PC3, KPL-4, or MCF7 tumor xenografts
製剤 Formulated in 0.5% methylcellulose/0.2% Tween-80
投薬量 ~100 mg/kg/day
投与方法 Orally

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Ipatasertib (GDC-0068) SDF
分子量 458


CAS No. 1001264-89-6
保管 2年-20℃
6月-80℃in solvent
別名 RG7440
溶解度 (25°C) * In vitro DMSO 92 mg/mL (200.87 mM)
エタノール 92 mg/mL (200.87 mM)
<1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one

カスタマーフィードバック (1)

Click to enlarge
Source , , Cell, 2015, 160(1-2): 161-76 . Ipatasertib (GDC-0068) purchased from Selleck
Method Western Blot
Cell Lines Sensory neurons
Concentrations 5 µM
Incubation Time 0、2、5、10 min
Results ATP-competitive inhibitor GDC-0068 significantly reduced MKK4 phosphorylation on Ser78 in axons after injury, and increased AKT phosphorylation on Thr308.

文献中の引用 (2)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related Akt 阻害剤

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • SC79

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • MK-2206 2HCl

    MK-2206 2HClは高度選択的に Akt1, Akt2 and Akt3を抑制して、 IC50がそれぞれ 8 nM, 12 nM と 65 nMになる。

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • AZD5363

    AZD5363は、有力なAkt阻害剤で、Akt1、Akt2とAkt3に作用すると、 IC50がそれぞれ 3 nM、 8 nM 、 8 nMです。

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401)は、4.7 nMのIC50による新しいAkt阻害剤です。

  • GSK690693

    GSK690693は、Akt1、Akt2とAkt3を目標としている汎Akt阻害剤で、IC50 がそれぞれ 2 nM、13 nM、9 nMです。

  • Triciribine

    Triciribineは、DNA合成阻害剤で、そのうえAktリン酸化とHIV-1を妨げます。IC50 がそれぞれ 130 nM と 20 nMです。


Tags: Ipatasertib (GDC-0068)を買う | Ipatasertib (GDC-0068)供給者 | Ipatasertib (GDC-0068)を購入する | Ipatasertib (GDC-0068)費用 | Ipatasertib (GDC-0068)生産者 | オーダーIpatasertib (GDC-0068) | Ipatasertib (GDC-0068)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description